Author

Sareena Rana

The Francis Crick InstituteORCID 0000-0002-3544-4184Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Julian DownwardiD· 4 shared Míriam Molina‐ArcasiD· 4 shared Mona TomaschkoiD· 3 shared Andrea de CastroiD· 2 shared Charles SwantoniD· 2 shared Chris MooreiD· 2 shared Claire E. PillsburyiD· 2 shared Emma ColliveriD· 2 shared

Activity by Year

2024-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Julian DownwardORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Oncogenic RAS activity is linked to immune priming and adenosine-driven immune evasion in lung adenocarcinoma

Sophie de Carné Trécesson, Philip East, Claire E. Pillsbury, Mariana Silva dos Santos, Hongui Cha, Emma Colliver, Tegan Gilmore, Sareena Rana, Chris Moore, Scott Lighterness, Deborah R. Caswell, Jesse Boumelha, Mona Tomaschko, Romain Baer, Jim E. Eyles, , Julian Downward

This study links oncogenic RAS activity to immune priming and adenosine-driven immune evasion in lung adenocarcinoma, showing both pro-immunogenic and immunosuppressive effects.

bioRxiv · Nov 25, 2025 · PreprintCancer Biology

Leveraging death of drug-sensitive cancer cells to promote immune-mediated bystander killing of subclones of drug-resistant tumor cells

Mona Tomaschko, KangBo Ng, Christopher Moore, Claire E. Pillsbury, Sareena Rana, James Campbell, Saptaparna Mukherjee, Ania Mikolajczak, Panayiotis Anastasiou, Andrea de Castro, Alicia Alonso de la Vega, Sophie de Carné Trécesson, Nathan W. Goehring, Míriam Molina‐Arcas, Julian Downward

This study shows that targeting drug-sensitive cancer cells with G12Ci inhibitors and combining it with immune therapies can eliminate drug-resistant subclones through immune-mediated bystander killing.

bioRxiv · Oct 27, 2025 · PreprintCancer Biology

Covalent inhibitors of the RAS binding domain of PI3Ka impair tumor growth driven by RAS and HER2

Joseph E. Klebba, Nilotpal Roy, Steffen M. Bernard, Stephanie Grabow, Melissa A. Hoffman, Hui Miao, Junko Tamiya, Jinwei Wang, Cynthia Berry, Antonio Esparza-Oros, Richard D. Lin, Yongsheng Liu, Marie Pariollaud, Holly Parker, Igor Mochalkin, , Matthew P. Patricelli

The paper develops covalent inhibitors targeting the RAS binding domain of PI3Kα, showing efficacy against RAS and HER2-driven tumors without affecting glucose homeostasis.

Science · Oct 9, 2025Peer-reviewedCancer Biology

Spatial proteomic analysis of a lung cancer model reveals regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses

Megan Cole, Panayiotis Anastasiou, Claudia Lee, Xiaofei Yu, Andrea de Castro, Jannes Roelink, Chris Moore, Edurne Mugarza, Martin L. Jones, Karishma Valand, Sareena Rana, Emma Colliver, Mihaela Angelova, Katey S.S. Enfield, Alastair J. Magness, , Febe van Maldegem

The paper identifies regulatory T cells as mediators of resistance to KRAS-G12C inhibitors and anti-PD-1 therapy through spatial proteomic analysis of lung cancer models.

Science Advances · Nov 1, 2024Peer-reviewedCancer Biology